The epidermal growth factor receptor has become one of the targets of anticancer drug research and development because of its widely distribution in several human tumor cells including non-small cell lung cancer. Based on molecular docking, a novel series of 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives have been synthesized and their biological evaluation for anti-proliferative activities on the human pulmonary carcinoma cell line A549 and EGFR inhibitory activities in vitro has been finished. According to the screening result, the target compound 7-(4-ethoxyphenyl)-4-(4-methoxylbenzylamino)-5,6,7,8-tetrahydrobenzo [4,5] thieno [2,3-d] pyrimidine (6d) and 7-(4-hydroxyphenyl)-4-(4-methoxylbenzylamino)-5,6,7,8-tetrahydrobenzo[4,5]thieno [2,3-d]pyrimidine (8d) demonstrated significant anti-tumor activity, and the preliminary structure-activity relationships of the target compounds were summarized. They were worthy of further modification to obtain more potent anticancer candidate drugs.